BridgeBio Pharma Price To Earning vs. Cash And Equivalents
| BBIO Stock | USD 23.42 0.18 0.77% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.92 | 0.7371 |
|
|
For BridgeBio Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BridgeBio Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BridgeBio Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BridgeBio Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BridgeBio Pharma over time as well as its relative position and ranking within its peers.
BridgeBio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BridgeBio Pharma Cash And Equivalents vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BridgeBio Pharma's current stock value. Our valuation model uses many indicators to compare BridgeBio Pharma value to that of its competitors to determine the firm's financial worth. BridgeBio Pharma is rated below average in price to earning category among its peers. It is rated fourth in cash and equivalents category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BridgeBio Pharma's earnings, one of the primary drivers of an investment's value.BridgeBio Cash And Equivalents vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
BridgeBio Pharma |
| = | (13.72) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
BridgeBio Pharma |
| = | 715.71 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
BridgeBio Cash And Equivalents Comparison
BridgeBio Pharma is currently under evaluation in cash and equivalents category among its peers.
BridgeBio Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BridgeBio Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BridgeBio Pharma will eventually generate negative long term returns. The profitability progress is the general direction of BridgeBio Pharma's change in net profit over the period of time. It can combine multiple indicators of BridgeBio Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 31 K | 32.5 K | |
| Net Interest Income | -63.3 M | -60.1 M | |
| Interest Income | 18 M | 18.9 M | |
| Operating Income | -607.4 M | -577 M | |
| Net Loss | -653.3 M | -620.6 M | |
| Income Before Tax | -653.3 M | -620.6 M | |
| Total Other Income Expense Net | -45.9 M | -43.6 M | |
| Net Loss | -433.1 M | -454.7 M | |
| Net Loss | -653.3 M | -620.6 M | |
| Income Tax Expense | 71.5 M | 75.1 M | |
| Non Operating Income Net Other | 124.2 M | 130.4 M | |
| Change To Netincome | 129.6 M | 136.1 M | |
| Net Loss | (3.95) | (4.15) | |
| Income Quality | 0.81 | 0.94 | |
| Net Income Per E B T | 0.98 | 0.74 |
BridgeBio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BridgeBio Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BridgeBio Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BridgeBio Pharma's important profitability drivers and their relationship over time.
Use BridgeBio Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.BridgeBio Pharma Pair Trading
BridgeBio Pharma Pair Trading Analysis
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BridgeBio Pharma position
In addition to having BridgeBio Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
To fully project BridgeBio Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BridgeBio Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BridgeBio Pharma's income statement, its balance sheet, and the statement of cash flows.